MYOK - MyoKardia Inc
Form 10-Q Period: JUN.30.18 Date Filed: AUG.08.18
Transcript Split
  
  
     
Move to First Section Move to Last Section
INDEX
ItemizedPage-by-Page
  Form 10-Q (Entire Filing)

Filing Body

Page 1: UNITED STATES

Page 2: MYOKARDIA, INC.

Page 3: PART I FINANCIAL INFORMATION

Page 4: MYOKARDIA, INC.

Page 5: MYOKARDIA, INC.

Page 6: MYOKARDIA, INC.

Page 7: MYOKARDIA, INC.

Page 8: MYOKARDIA, INC.

Page 9: MYOKARDIA, INC.

Page 10: MYOKARDIA, INC.

Page 11: MYOKARDIA, INC.

Page 12: MYOKARDIA, INC.

Page 13: MYOKARDIA, INC.

Page 14: MYOKARDIA, INC.

Page 15: MYOKARDIA, INC.

Page 16: MYOKARDIA, INC.

Page 17: MYOKARDIA, INC.

Page 18: MYOKARDIA, INC.

Page 19: MYOKARDIA, INC.

Page 20: You should read the following management s discussion and analysis of our financial condition and re

Page 21: Sanofi License and Collaboration Agreement

Page 22: Critical Accounting Policies and Significant Judgments and Estimates

Page 23: Results of Operations

Page 24: Interest and Other Income, Net

Page 25: Interest and Other Income, Net

Page 26: Cash Flows

Page 27: Off-Balance Sheet Arrangements

Page 28: PART II OTHER INFORMATION

Page 29: We will need to raise additional funding, which may not be available on acceptable terms, or at all.

Page 30: Our reported financial results may be adversely affected by changes in accounting principles general

Page 31: Risks Related to Our Precision Medicine Platform and the Discovery and Development of Our Product Ca

Page 32: Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain

Page 33: N/A

Page 34: We may find it difficult to enroll patients in our clinical trials, which could delay or prevent cli

Page 35: We may not be successful in our efforts to identify or discover potential product candidates.

Page 36: Risks Related to Government Regulation

Page 37: Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or

Page 38: We may seek one or more special designations from regulatory authorities for our product candidates,

Page 39: Risks Related to Our Reliance on Third Parties

Page 40: We expect to rely on third parties to conduct some or all aspects of our protocol development, resea

Page 41: We contract with third parties for the manufacture of our product candidates for preclinical and cli

Page 42: Risks Related to Our Intellectual Property

Page 43: We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, wh

Page 44: We may be subject to claims that our employees, consultants or independent contractors have wrongful

Page 45: If we are unable to establish sales and marketing capabilities or enter into agreements with third p

Page 46: Risk Related to Our Business and Industry

Page 47: We face significant competition from other biotechnology and pharmaceutical companies, and our opera

Page 48: Public opinion and heightened regulatory scrutiny of precision medicine for the treatment of cardiov

Page 49: Our future success depends on our ability to retain key employees and consultants, including our sci

Page 50: We will need to expand our organization and we may experience difficulties in managing this growth,

Page 51: If we fail to comply with environmental, health and safety laws and regulations, we could become sub

Page 52: We or the third parties upon whom we depend may be adversely affected by earthquakes or other natura

Page 53: Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be

Page 54: Future sales and issuances of our common stock or rights to purchase common stock, including pursuan

Page 55: Our principal stockholders and management own a significant percentage of our stock and will be able

Page 56: We will continue to incur increased costs as a result of operating as a public company, and our mana

Page 57: Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable futur

Page 58: N/A

Page 59: EXHIBIT INDEX

Page 60: SIGNATURES

Exhibits

Interactive Data

   CURRENT PAGE
    Download Current Page as a Word Document  Download Current Page as a PDF Document    Download Excel File of Financials